Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Sirolimus (Primary)
  • Indications Carcinoma; Chondrosarcoma; Chordoma; Colorectal cancer; Ewing's sarcoma; Fibroma; Head and neck cancer; Hodgkin's disease; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant fibrous histiocytoma; Malignant melanoma; Non-small cell lung cancer; Osteosarcoma; Perivascular epithelioid cell tumours; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 25 Apr 2023 Results assessing safety and efficacy of mTOR inhibitor nab-sirolimus when combined with the immune checkpoint inhibitor nivolumab published in the Anticancer Research.
    • 02 Dec 2021 Status changed from recruiting to completed.
    • 05 May 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top